Community Pharmacy England (CPE) - News updates

Community Pharmacy England’s Committee needs to know what you think about the 2026/27 CPCF settlement. This year’s settlement includes a 10.3% (£340m) funding increase, regulatory progress, and plans to introduce Independent Prescribing into Pharmacy First and the Contraception Service. However, Community Pharmacy England continues to warn of a sector in crisis and only agreed to [...] The post Sector Poll: What do you think of the new CPCF arrangements? appeared first on Community Pharmacy England.

Following discussions with NHS England, we have agreed to an extension of the pilot flu vaccination service for children aged 2-3 years, with an increase in the fee. In addition, after successful lobbying, the service is being expanded to include opportunistic vaccination of two additional groups: Clinically at-risk children aged 2 years to less than [...] The post Expanded Children’s Flu Vac Advanced service to be launched in October appeared first on Community Pharmacy England.

Following the recent announcement of the CPCF 2026/27 funding settlement, we know many of you have questions about what it means in practice for your pharmacy and your patients. To help provide clarity, we have answered some Frequently Asked Questions we’re hearing from pharmacy owners. Q. What is the expected change in income for an average pharmacy? In [...] The post CPCF Settlement 2026/27: Frequently Asked Questions appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Mirtazapine 30mg Tablets (Cadila Pharmaceuticals) Drug alert number: EL(26)A/28 Date issued: 08 June 2026 Cadila Pharmaceuticals Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of a batch of Mirtazapine 30mg Film-Coated Tablets distributed in Crescent Pharma Limited livery. DMRC [...] The post MHRA Class 4 Medicines Defect Notification: Mirtazapine 30mg Tablets (Cadila Pharmaceuticals) (Crescent Pharma Limited livery) appeared first on Community Pharmacy England.

Community Pharmacy England is pleased to announce that Rahul Sharda, an independent pharmacy owner from Stoke-on-Trent, is the new Regional Representative Committee Member for the East and North Midlands. Rahul joins the Community Pharmacy England Committee and will serve in this role until 31st March 2027, in line with the current committee term. To find [...] The post New East and North Midlands Regional Representative appeared first on Community Pharmacy England.

Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has redetermined the May 2026 concessionary prices for Indometacin 25mg capsules & Sumatriptan 50mg tablets. Product Pack size Price concession Indometacin 25mg capsules 28 £11.20 (previously £10.24) Sumatriptan 50mg tablets 28 £6.26 (previously £5.85) [...] The post Improved prices for Indometacin 25mg capsules & Sumatriptan 50mg tablets for May 2026 appeared first on Community Pharmacy England.

Following the announcement of the 2026/27 negotiations, a Drug Tariff update has been published to base the New Medicine Service (NMS) monthly consultation cap on 0.9% rather than 1.0% of monthly prescriptions. This change is unlikely to impact the majority of pharmacy owners; however, pharmacy owners are encouraged to review the new caps, as shown [...] The post NMS: Change to monthly cap from June 2026 appeared first on Community Pharmacy England.

Community Pharmacy England’s webinar on the new funding settlement is now available to watch on-demand. Following last week’s CPCF announcement, we’ve been preparing for events and producing a variety of resources to help pharmacy owners understand the key elements of the Community Pharmacy Contractual Framework (CPCF) settlement for 2026/27. During the webinar held earlier this [...] The post Webinar recording: 2026/27 CPCF settlement appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Ponlimsi (Denosumab) 60mg Solution for Injection in Pre-filled Syringe (Teva UK Ltd) EL(26)A/27 DMRC reference number: DMRC- 39320587 Date issued: 4 June 2026 Teva UK Limited is reporting a labelling error on the carton for Ponlimsi (Denosumab) 60mg Solution for injection in Pre-filled Syringe. The carton states “For application to [...] The post MHRA Class 4 Medicines Defect Notification: Ponlimsi (Denosumab) 60mg Solution for Injection in Pre-filled Syringe (Teva UK Ltd) appeared first on Community Pharmacy England.

Update 04/06/2026: Changes in the alert below are in bold Update 08/01/2026: Alzest transdermal patches (Dr Reddy’s Laboratories (UK) Ltd) in all strengths have been discontinued. Please note: Care is needed if switching between daily and twice weekly (Zeyzelf) rivastigmine patches to avoid the risk of dosing error. The Department of Health and Social Care (DHSC) [...] The post Medicine Supply Notification: Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches – updated appeared first on Community Pharmacy England.